InvestorsHub Logo
Followers 97
Posts 3945
Boards Moderated 0
Alias Born 07/31/2020

Re: ITYS post# 40968

Wednesday, 05/15/2024 10:47:52 AM

Wednesday, May 15, 2024 10:47:52 AM

Post# of 41243
Doing the math.

The primary use of the capital over the next 12 months will be to establish and scale up manufacturing capabilities. This is a critical step in commercializing our technology, as it will enable us to produce at a volume necessary to meet market demand. Additionally, the funding will be allocated towards obtaining necessary performance testing, certifications, and regulatory approvals, which are crucial for market entry, especially in industries that are heavily regulated. This process will ensure that our products not only meet the highest standards of quality and safety but also comply with industry-specific regulations. Furthermore, a portion of the capital will be dedicated to strengthening our supply chain and logistics framework, ensuring that we can deliver our products efficiently and reliably to our customers.



I agree, doing the offering at 5xs the current price support based on SEC approval would be a pipe dream IMO. Given the stock has no liquidity is all the proof one needs.

As I mentioned last week, SEC approval might result in a modest, albeit unsupported, increase in price. Observing management's disinterest in prematurely marketing (pump and dump) the story suggests they possess a deeper comprehension than many OTC companies regarding the necessary steps to enhance shareholder value.

I personally see this offering as a path to line up the ducks ahead of a PO. In order to bring a customer to the table, the company needs to show how they intend to raise the necessary capital to "scale up manufacturing". Investors should note which use of the funds is FIRST listed under "primary use of the capital".

It is critical that a company has the ability to show its customers that they have the financial backing to full fill the order. Without it, the PO would be worthless.
Bullish
Bullish